


INVESTOR PRESENTATION · OCTOBER 2026

Defence Therapeutics

Unlocking the Power of Cancer Drugs





IMPORTANT NOTICE

Forward-Looking Statements

This presentation contains forward-looking information within the meaning of applicable Canadian securities laws, including statements about Defence Therapeutics Inc.'s ("Defence" or the "Company") business and corporate strategy, its Accum[®], ADC, radiotherapeutics and AccuTOX[®] programs, anticipated trials, products, partnerships, and future financial or operating performance. Forward-looking information can typically be identified by words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "continue," "plans," or similar expressions, and reflects the Company's current opinions, estimates and assumptions, which may prove incorrect.

Forward-looking information is subject to numerous risks and uncertainties, including Defence's short operating history and lack of product sales revenue or profitability to date, and the risks inherent in completing clinical development of, and obtaining regulatory approval for, its product candidates. While Defence believes it has identified the material risk factors, other risks not presently known to it, or currently believed immaterial, could also cause actual results to differ materially from those expressed or implied. There can be no assurance that this forward-looking information will prove accurate.

All forward-looking information speaks only as of the date of this presentation, or the date otherwise indicated, and is expressly qualified by this cautionary statement. Defence undertakes no obligation to update it except as required by law. This presentation is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities of the Company.



COMPANY SNAPSHOT

Defence Therapeutics at a Glance

LISTINGS

CSE: DTC · OTCQB: DTCFF · FSE: DTC

LOCATIONS

Montreal, Quebec, Canada
Hamilton, Ontario, Canada

FOCUS

Precision oncology via The **Accum**® Platform
Enhancing intracellular deliver of cancer drugs

INTELLECTUAL PROPERTY

8 granted U.S. patents
Multiple worldwide patents and applications

LEADERSHIP

New CEO and COO/Head of Radiopharm (Aug 2026)
Three new board additions: in ADC, translational science and finance

LEAD PROGRAMS

1. **AccuTOX**® - clinical stage asset (Melanoma, head & neck)
2. Accum®-enabled **radiotherapeutics** (Fully owned; In-house)
3. Accum®-enhanced **ADCs** (Partnering)

MARKET SNAPSHOT

\$37.3M CAD

Market capitalization (approx., Sept 2026)

75.8M

Common shares outstanding

\$9.6M

Gross proceeds — March 2026 financing

~\$21M CAD

Potential warrant proceeds;
\$0.65-\$1.00 expiring from Jan 2027 - Mar 2028

\$0.365 – \$0.93

52-week trading range per Sept 2026 (CSE: DTC)

Figures approximate and as of the dates indicated.



THE PROBLEM

Powerful Oncology Therapies. Persistent Biological Barriers.

Checkpoint Inhibitors | Targeted Radiopharmaceuticals | Antibody-Drug Conjugates



POWERFUL THERAPIES

Checkpoint inhibitors (CPIs), antibody-drug conjugates (ADCs), and target radio-pharmaceutical (TRPs) have transformed cancer treatment — delivering some of the most powerful therapies in oncology.

Yet, these therapies struggle to deliver their potential, often due to cancer's innate defence mechanisms.



BIOLOGICAL BARRIERS

CPIs — insufficient immune recognition limits therapeutic response.

TRPs — limited tumor uptake and retention constrain radiation delivery.

ADCs — inefficient intracellular drug delivery limits efficacy.


The full potential of today's most powerful cancer drugs remains constrained by fundamental biological barriers.



THE SOLUTION

The Accum® Platform: Unlocking the Full Potential of Oncology's Most powerful Therapies

The Accum® Platform combines two nature-inspired mechanisms—endosomal escape and nuclear localization—to overcome intracellular barriers that can limit therapeutic performance.



BROADLY APPLICABLE

Immuno-oncology • Radiopharmaceuticals • ADCs
+ Vaccines • RNA • Oligonucleotides

PLUG-AND-PLAY

Designed to integrate with existing and in-development therapeutics without redesigning the underlying drug.

PROTECTED PLATFORM

8 granted US patents with multiple applications worldwide



WHY DEFENCE THERAPEUTICS, WHY NOW

One Platform. Multiple Paths to Value. Execution Underway.



Differentiated Oncology Platform

- **Accum®** is designed to enhance established and next-generation cancer therapeutics
- Applicable across CPI, targeted radiopharmaceuticals, and ADCs
- Supported by a strong portfolio of granted patents
- Not a single-asset drug play — A Technology Company



High-Value Commercial Opportunities

- **AccuTOX®** — clinical-stage immuno-oncology opportunity
- **Radiopharmaceuticals** — developing proprietary Accum®-enabled assets
- **ADCs** — partnership and licensing strategy targeting near-term value creation



Partnering Engine Already Running

- Commercial ADCs profiled for partner-ready data
- Global pharma/biotech engagements underway for Accum®-enabled ADCs
- Scalable, non-exclusive licensing model: upfront revenue → milestones → royalties



Leadership & Capital to Execute


- New CEO and COO —partnering and development experience
- Board strengthened with experienced industry leadership
- \$9.6M financing completed in Q12026
- Pending capital raise to advance clinical asset targeting **Q12027**



MULTIPLE PATHS TO VALUE

One Platform. Multiple Paths to Value.

Focused investment across three pillars where Accum® can create differentiated clinical and commercial value





PILLAR 1 OF 3

Making Tumors More Visible to the Immune System

AccuTOX® combines direct tumor killing with enhanced antigen presentation to amplify checkpoint inhibitor activity

~2x


Increase in MHC-I antigen presentation on tumour cells following AccuTox treatment

~85%

Slower tumour growth with combination therapy in laboratory models

100%

Survival across all treated laboratory animals, with no observed toxicity signals



WHAT THIS MEANS

Injected directly into tumours, AccuTOX® kills cancer cells while increasing tumour antigen presentation—helping the immune system better recognize cancer. This provides strong rationale for combining AccuTOX® with checkpoint inhibitors to unleash T cells against tumour targets.

In preclinical models, this complementary mechanism resulted in substantial tumour-growth suppression and prolonged survival when combined with checkpoint inhibitors.

**Anti-PD-1 (Keytruda®) is an approved immuno-oncology therapy by Merck (MSD). Results shown are preclinical and have not been demonstrated in humans yet.*



PILLAR 1 OF 3

Positioning AccuTOX® for Clinical Development and Value Creation

Clinical-stage asset with regulatory clearance and trial infrastructure in place

OUR MOST CLINICALLY ADVANCED ASSET

Regulatory path established

Health Canada and FDA clearance to initiate Phase I development
Study May Proceed and No Objection Letters received for AccuTOX® in melanoma

Clinical infrastructure in place

Clinical sites identified and experienced clinical operations team established
Infrastructure positioned for efficient Phase I activation and execution

Value-maximizing strategy under review

Independent technical/commercial review underway to optimize development and monetization paths; options for development, partnering or out-licensing

MARKET OPPORTUNITY

~2M Patients Annually

ICI-treated solid-tumor population with injectable lesions
Melanoma • Head & Neck • Bladder • Lung • Breast

LEAD MARKET

Melanoma

PD-1-Refractory

~\$560M

GLOBAL SOM

Projected Annual sales by 2033

EXPANSION MARKET

Head & Neck Cancer

~\$3B

MARKET #3

Bladder

~\$2B

Illustrative market estimates based on annual PD-1/ICI-refractory addressable populations, \$65,000 assumed treatment cost and 40% penetration for SOM. USD.



PILLAR 2 OF 3

Building a Proprietary Pipeline of Accum[®]-Enabled Radiopharmaceuticals

Targeted radiopharmaceuticals are emerging as a new class of cancer therapy but constrained by limited tumour uptake and retention.

WHY CAN THE ACCUM[®] PLATFORM ENABLE BETTER RADIOPHARMACEUTICALS?

By increasing intracellular delivery and retention, Accum[®] has the potential to concentrate therapeutic radioisotopes within tumour cells—where their radiation can have the greatest effect.

2026-2027 PRIORITY

- Advance proprietary Accum[®]-enabled candidates toward **IND-enabling development within 12-18 months**



New Leadership

Dr. Ryan Simms

COO & Head of Radiopharmaceutical Programs

20+ years in radiopharmaceutical development, with leadership roles at Fusion Pharmaceuticals, Abdera Therapeutics, and the Centre for Probe Development and Commercialization. At Fusion, led chemistry, radiochemistry, manufacturing, and partnerships before its ~US\$2B acquisition by AstraZeneca in 2024.





PILLAR 2 OF 3

Expanding Accum® into High-Value Radiopharmaceuticals

STRATEGIC LOCATION

Positioned in a Leading Radiopharmaceutical Hub



Established a presence in Hamilton to access one of Canada's strongest radio-pharmaceutical ecosystems, including specialized talent, infrastructure and industry expertise.

MARKET VALIDATED WITH RECENT M&A DEALS

Lantheus × Evergreen Theragnostics **~\$1.0B**

*PET diagnostic OCTEVY; preclinical and clinical programs
April 2025*

Bristol Myers Squibb × Philochem **~\$1.4B**

*Phase 1 OncoACP3 diagnostic with preclinical prostate cancer program
June 2025*

Regeneron × Telix **~\$2.1B**

*4 programs; Telix radiopharma capabilities with Regeneron antibody
April 2026*

Oncology radiotherapeutics market is expected to reach \$16B by 2033.



PILLAR 3 OF 3

Accum[®] Enhances HER2 ADCs Across Multiple Breast Cancer Models

~20x


Greater anti-tumour efficacy in vivo models with Accum[®]-T-DM1[®] vs. T-DM1 alone

2 Marketed ADCs

Enhancement demonstrated with both T-DM1 and T-DXd

Difficult-to-treat models

Activity demonstrated in resistant and lower-HER2-expressing breast cancer models



WHAT THIS MEANS

Accum[®] has demonstrated enhancement of two marketed HER2 ADCs across multiple breast cancer models, including ADC-resistant models. By improving intracellular delivery, Accum[®] has the potential to increase potency, overcome resistance and extend efficacy to lower target-expressing tumours — without changing the antibody, target or payload. Greater potency at lower doses could improve the therapeutic index, delivering greater efficacy with the potential for reduced toxicity.

Kadcyla[®] (T-DM1; Genentech/Roche) and Enhertu[®] (T-DXd; Daiichi Sankyo/AstraZeneca) are approved HER2-directed ADCs. Accum[®] combinations are investigational; results shown are preclinical only.



PILLAR 3 OF 3

Drive Accum® Adoption Through Partnerships & Scalable Licensing Model

MARKET VALIDATED WITH MULTIPLE RECENT LICENCING DEALS

Astellas × Evopoint Biosciences ~\$1.3B

ADC with a proprietary linker technology · 2024

Boehringer Ingelheim × Synaffix ~\$1.3B

Multi-target platform license · 2025

Roche × MOMA ~\$2.0B

ADC engineering platform · 2024

Oncology radiotherapeutics market is expected to reach **\$30B by 2033**.

WE ENABLE, NOT COMPETE

Our objective is not to develop competing ADCs, but to enable ADC developers — engaging companies whose assets could benefit from Accum® to establish partnerships.

COMMERCIAL MODEL

Drive adoption through revenue-generating partnerships and licenses; reinvest proceeds into emerging applications, including RNA and oligonucleotide payload delivery.

NEAR-TERM PRIORITY

Identify new ADC collaborations over the next twelve months to evaluate Accum® across a broader range of partnered assets.



BUSINESS MODEL

Partnership-Led Licensing Model

1



Partner Brings the Asset

An ADC or biologic developer contributes a clinical or preclinical asset and funds profiling.

2



Defence Applies Accum®

Accum® is evaluated to enhance intracellular delivery, potency and tolerability of the partnered asset.

3



Licensing Revenue

Defence earns upfront assessment fees, development milestones and, later, royalties as the partnered program advances.

4



Reinvest in the Pipeline

Proceeds fund AccuTOX®, radiotherapeutics, and emerging payloads such as RNA and oligonucleotides.



LEADERSHIP

An Experienced Team Leading the Next Stage of Company Growth



Dr. Amie Phinney, PhD, MBA

President & Chief Executive Officer, Board Director

20+ years in international biotech leadership, including Abbott, AbbVie, CSO of Lakeside Discovery, and BD leadership at adMare BioInnovations. Co-founder and inaugural CEO of Block Biosciences. PhD, University of Basel; MBA, Lake Forest School of Management, USA.



abbvie



LakesideDiscovery **DEERFIELD**
Advancing Healthcare



Sébastien Plouffe

Executive Chairman & Founder, Board Director

Founded Defence and built the Accum® platform and scientific foundation. Transitioned to Executive Chairman in August 2026, retaining focus on strategy, financing, partnerships and governance.

Scotia
Wealth Management





GOVERNANCE

An Expanded Board Adds Deep Scientific and Business Experience



New!

Dr. John Lambert

Board Director — ADC Pioneer



40+ years in ADC science. Former Chief Scientific Officer and EVP of Research at ImmunoGen, where his work contributed to Kadcyla®, Sarclisa® and Elahere®. Among the earliest ADC researchers at Dana-Farber Cancer Institute. 130+ peer-reviewed publications; Fellow, AIMBE. PhD in Biochemistry, Cambridge.




New!

Sherry Aulin

Board Director — Finance Expert



Accomplished C-suite executive with a proven track record of shaping strategy, leading multidisciplinary teams, and driving capital markets initiatives to support pipeline and organizational growth. Experienced in scaling companies from private to public, building drug development capabilities, and preparing for commercialization.



New!

Dr. John Beaver

Board Director — Translational Science



20+ years in pharmaceutical leadership. Most recently, VP & Head of Global Biomarker Discovery & Development at Biogen, supporting ~48 pipeline programs. Prior roles at AbbVie and GlaxoSmithKline. Contributed to FDA accelerated approvals in Alzheimer's disease and ALS.



Dr. Philippe Lefrançois

Board Director — Translational Science



Dermatologist and clinician-scientist with expertise in translational skin cancer research, genomics, biomarker discovery, and tumor biology. Director of Research in McGill University's Division of Dermatology, with experience advancing novel cancer therapeutics and diagnostics toward preclinical and early clinical development.



GOVERNANCE

A Scientific Advisory Board with Broad Scientific Expertise



Rob Leanna

ADC & Biologics Manufacturing

abbvie



Danny Chui

Antibody & ADC Engineer

zymeworks **AMGEN**



Dr. Sarkis Meterissian

Oncology researcher & physician

 McGill University
Health Centre



Dr. Svetlana Selivanova

Radiotherapeutics Expert

 Canadian Nuclear
Laboratories



ROADMAP

What to Expect Over the Next Twelve Months

Defined milestones across each strategic pillar



ACCUTOX®

Define the highest-value commercialization path

Update clinical development plan and targeted trial start date

Initiate AccuTOX® clinical trial or execute out-licensing/partner agreement



RADIOTHERAPEUTICS

Generate foundational Accum® data

Select priority radioisotope–target combinations for advancement

Advance proprietary Accum®-enabled candidate toward IND-enabling development



ADC PARTNERSHIPS

Expand Accum®-ADC profiling with partners

Generate partner-ready data across priority ADC assets

Execute revenue-generating licensing agreements



SUMMARY

Investment Highlights



Differentiated, IP-protected platform

8 U.S. granted patents and preclinical data demonstrating enhancement of multiple biologic drug categories



Three distinct paths to value creation

AccuTOX[®] immuno-oncology, Accum[®]-enabled radiopharmaceuticals and ADC partnerships/licensing



Clinical-stage asset with strategic optionality

AccuTOX[®] provides a near-term path to clinical development or partnering/out-licensing.



Capital-efficient commercialization strategy

Partner-led ADC business model designed to generate near-term revenue, with milestone and royalty revenue streams



Defined 12-month milestones

Clear catalysts across AccuTOX[®], radiopharmaceuticals and ADC partnering, supported by a strengthened organization



Experienced leadership built for execution

Leadership and Board spanning pharma, biotech, translational medicine and partnering.

Public-market access to an oncology platform approaching multiple potential value inflection points across clinical development, proprietary pipeline creation and partnering



LOOKING AHEAD

Thank You for Your Continued Confidence.

“With a differentiated technology platform and a focused strategy, Defence is well positioned to translate years of scientific innovation into programs and partnerships that can define our future.”

— Dr. Amie Phinney, PhD, MBA, President & Chief Executive Officer

WEBSITE

defencetherapeutics.com

PHONE

+1 (604) 306-8027

INVESTOR EMAIL

info@defencetherapeutics.com

LISTINGS

CSE: DTC · OTCQB: DTCFF · FSE: DTC